Synthetic Biologics (SYN) Stock Price Up -9.1%

Shares of Synthetic Biologics Inc (NYSEAMERICAN:SYN) rose 9.1% on Thursday . The company traded as high as $0.45 and last traded at $0.40. Approximately 589,529 shares changed hands during mid-day trading, a decline of 27% from the average daily volume of 809,710 shares. The stock had previously closed at $0.44.

A number of equities analysts have recently issued reports on the stock. BidaskClub cut shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a research note on Saturday, November 4th. Zacks Investment Research cut shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th.

The firm has a market capitalization of $56.58, a P/E ratio of -1.86 and a beta of 1.08.

An institutional investor recently raised its position in Synthetic Biologics stock. Citadel Advisors LLC boosted its stake in shares of Synthetic Biologics Inc (NYSEAMERICAN:SYN) by 312.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 241,797 shares of the company’s stock after acquiring an additional 183,120 shares during the quarter. Citadel Advisors LLC owned approximately 0.19% of Synthetic Biologics worth $122,000 as of its most recent SEC filing.

ILLEGAL ACTIVITY WARNING: “Synthetic Biologics (SYN) Stock Price Up -9.1%” was published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit